China, which now conducts more clinical drug trials than the US, still lags in the quality and commercial reach of its biomedical science, according to a recent survey of senior US leaders in industry and academia. The ‌poll, conducted by Cure Innovation Index, found that China is seen as the clear leader in two out of six sectors: clinical development and supply chain. It found that the US leads in moving experimental products through to large-scale production, capital, and commercialisation...